Journal
FRONTIERS IN ONCOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2023.1205720
Keywords
rituximab; steroid-refractory pancreatitis; immune-related adverse event; atezolizumab; immune checkpoint inhibitors
Categories
Ask authors/readers for more resources
The use of immune checkpoint inhibitors can cause immune-related adverse events, including pancreatitis. Steroids are commonly used to treat pancreatitis induced by immune checkpoint inhibitors. However, little is known about the management of steroid-refractory cases. This case presentation suggests that rituximab may be an effective treatment option for such cases.
The use of immune checkpoint inhibitors (ICIs) for treating several types of cancer is increasing, but they may be associated with immune-related adverse events (irAEs). Pancreatitis is a rare irAE, mostly responsive to steroid treatment. There are no published data on the management of steroid-refractory ICI-induced pancreatitis. Rituximab has shown efficacy in the setting of relapsing non-ICI-induced autoimmune pancreatitis. However, its use has not been tested for treating immunotherapy-related pancreatitis. Here, we present the case of a patient with steroid-refractory immune-related pancreatitis successfully treated with rituximab as a potential strategy for irAE management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available